# A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Source: https://onco.cc/trials/nct07277231/  
OnCo record `nct07277231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.

## Summary

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia is a phase 3 interventional study registered as NCT07277231 by BeOne Medicines, with 500 participants planned, started 2026-01-22 and due to reach its primary completion in 2031-02. Interventions recorded: Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07277231
- Phase: 3
- Setting: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Sponsor: BeOne Medicines
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT07277231: https://clinicaltrials.gov/study/NCT07277231

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct07277231.json